Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Supernus, Inc. Common Stock

SUPN

Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.

Last trade $29.22
Day change +$0.39 (+1.35%)
Day range $28.48 – $29.69
Volume 1,591,465
Market cap $5.99B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for SUPN.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for SUPN.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Why Indivior Pharmaceuticals Stock Topped the Market Today

Indivior Pharmaceuticals completed its merger with Supernus Pharmaceuticals on November 2, 2026, creating a leading CNS biopharmaceutical company. The combined entity will operate under the Supernus name and ticker, with Indivior shareholders receiving a $1 billion special cash dividend and owning approximately 56.5% of the merged company. The merger aims to achieve $125 million in annual cost synergies.

Zacks Investment Research

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

Supernus Pharmaceuticals beat Q3 2026 earnings expectations with $0.93 EPS versus consensus of $0.49, representing an 89.80% surprise. Revenue of $226.77 million also exceeded estimates by 1.39%. However, the stock has underperformed the market by 17.3% year-to-date and carries a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends ahead of the earnings release.

Zacks Investment Research

BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened

Biogen beat Q3 2026 earnings and revenue estimates with adjusted EPS of $2.62 and revenues of $2.80 billion. Growth drugs Skyclarys, Qalsody, Zurzuvae, and acquired Apellis products drove strong performance, with growth portfolio revenues rising ~50% year-over-year. However, legacy MS portfolio declined 13% and biosimilar sales fell 19%. The company tightened 2026 EPS guidance to $15.95-$16.75 while maintaining mid-single-digit revenue growth expectations.

GlobeNewswire Inc.

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

Supernus Pharmaceuticals announced that the FDA has granted seven years of orphan-drug market exclusivity for ONAPGO (apomorphine HCl), a subcutaneous infusion device for treating motor fluctuations in advanced Parkinson's disease patients. The exclusivity period began February 3, 2025. Additionally, the company submitted a supplemental New Drug Application for a second supplier with expected FDA approval by mid-2027.

The Motley Fool

Why Supernus Pharmaceuticals Stock Topped the Market Today

Supernus Pharmaceuticals announced a merger with Indivior Pharmaceuticals in an all-stock deal, creating a combined company with 11 FDA-approved drugs and anticipated $125 million in annual cost synergies. The stock rose 3% despite initial gains of 16%, reflecting cautious optimism. Q2 earnings showed 32% revenue growth to $219 million but a net loss of $58 million, missing earnings estimates while beating revenue forecasts.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Nov 3, 2026$8.13Nov 6, 2026special

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.